Equity Overview
Price & Market Data
Price: $9.02
Daily Change: +$0.22 / 2.44%
Daily Range: $9.02 - $9.20
Market Cap: $454,194,272
Daily Volume: 1,010
Performance Metrics
1 Week: 13.26%
1 Month: 1.73%
3 Months: -34.33%
6 Months: -15.63%
1 Year: 48.40%
YTD: -38.89%
Company Details
Employees: 371
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.